The Johnson & Johnson drug Darzalex showed promise in helping keep a precancerous condition from progressing to the blood ...

For patients with functional high-risk multiple myeloma, timely referral to specialized centers is needed, since access to ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer.

Saad Z. Usmani, MD, MBA, FACP, discusses how the AQUILA study data presented at ASH 2024, highlighting the benefits of early intervention in high-risk smoldering multiple myeloma, could impact ...

"This treatment was very well tolerated," he added. "We believe that with these data, patients with high-risk smoldering myeloma may benefit from immediate treatment with daratumumab and that ...

Many patients with multiple myeloma experience persistent pain and use opioids to manage that pain even after they achieve remission, a survey suggests.

Aimee Merino, MD, discusses how the treatment decision for a 60-year-old patient with early relapse/refractory multiple ...

Darzalex, a Johnson & Johnson drug, significantly reduces the risk of developing multiple myeloma in patients with high-risk smoldering myeloma. In trials, it showed a 51% reduction in disease ...